CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 22 enrolled
Drug / intervention
Ezetimibe +2 moredrug
Likely dose
Atorvastatin 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00319449
NCT00319449Phase 4Completed

A Single Center, Randomized, Parallel Groups, Placebo-Controlled Study Comparing The Efficacy, Safety, And Tolerability Of The Daily Co-administration Of Ezetimibe 10 Mg Or Ezetimibe Placebo To Ongoing Treatment With Atorvastatin 10 Mg In Subjects With Primary Hypercholesterolemia And Multiple Coronary Heart Disease Risk Factors in Indonesian Population.

Organon and Co·interventional·Posted Apr 27, 2006·Updated Feb 9, 2022

In Brief

A Phase 4 clinical trial evaluating Ezetimibe, Placebo, and 1 other intervention for Hypercholesterolemia and Coronary Arteriosclerosis. Completed, enrolled 22 participants.

Detailed Summary

This study is being conducted to compare the efficacy, safety, and tolerability of ezetimibe 10 mg coadministered with atorvastatin 10 mg versus atorvastatin 10 mg in Indonesian population with primary hypercholesterolemia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--

Timeline

Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 27, 2006
Enrollment StartSep 1, 2005
Primary CompletionOct 1, 2006
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 20.2 years ago

Interventions

Ezetimibedrug

10 mg ezetimibe, orally, daily for 6 weeks, added to ongoing treatment with 10 mg atorvastatin

Placebodrug

10 mg/day matching placebo to ezetimibe, orally, daily for 6 weeks, added to ongoing 10 mg atorvastatin

Atorvastatin 10 mgdrug

10 mg/day atorvastatin, orally, (ongoing treatment in participants)